#United States #San Francisco #Hagens Berman #FDA Safety #Medline Inc

Hagens Berman Investigates Medline Inc. for Potential Misconduct

Overview

In a significant move, Hagens Berman Sobol Shapiro LLP (HBSS), a prominent national shareholder rights law firm, has opened an investigation into Medline Inc. (NASDAQ: MDLN) examining whether the medical supply company misled its shareholders about the integrity of its manufacturing practices and adherence to FDA safety standards. The inquiry is precipitated by troubling reports of systemic issues concerning contamination protocols that may not have been disclosed adequately to investors, potentially constituting an instance of securities fraud.

Key Events Leading to the Investigation

Since its public offering in December 2025, Medline has publicly committed to high manufacturing standards, claiming that their extensive quality control team of over 2,400 ensures that all products meet rigorous expectations. However, the credibility of these claims has come under scrutiny following a warning letter from the FDA issued on May 28, 2026, outlining serious violations of the current good manufacturing practices (CGMP) at Medline's facilities.

The FDA's letter pinpointed various deficiencies, including:

• - Isolation of objectionable microorganisms: The FDA stated that Medline had identified harmful microorganisms in finished drug product samples on multiple occasions between June 2023 and August 2025.
• - Manufacturing environment contamination: At least five samples collected from the production sites showed signs of these harmful microorganisms since January 2025, indicating possible lapses in cleanliness or controls.
• - Inadequate investigations: There were also claims that Medline failed to conduct thorough investigations and implement corrective actions in response to these contamination incidents. This lack of response was previously noted in a previous FDA report from January 2025.

The concerning revelations led to a significant market response, causing a loss of approximately $2.2 billion in Medline's market capitalization post-announcement.

Legal Implications

Reed Kathrein, a key partner at Hagens Berman, has stated that the investigation will focus on whether Medline knowingly concealed the serious nature of these FDA concerns from its investors. The implications could be severe, as investors may have a legitimate claim based on the apparent discrepancies between the company's public assurances and actual safety practices.

HBSS is encouraging those who have significantly lost investments in Medline or possess pertinent information to come forward to assist in the investigation. Additionally, whistleblower provisions have been brought to light, with potential rewards for those providing valuable information leading to successful enforcement actions by the SEC.

Moving Forward

Hagens Berman, which boasts a strong track record of fighting for corporate accountability, has pledged to rigorously pursue the truth behind Medline's practices. Investors and stakeholders alike are left in a precarious position as further developments unfold regarding the company's safety and quality policies. As always, the importance of transparency and accountability within the corporate structure remains paramount, especially in industries where public safety and health are at stake.

In anticipation of further disclosures, industry observers will be watching closely. The ramifications of this investigation could lead to substantial shifts not only in Medline's operations but also in broader industry practices concerning compliance and safety standards in manufacturing.